Your session is about to expire
← Back to Search
Small Molecule Inhibitor
QUILT-3.031: AMG 337 in Subjects With Advanced or Metastatic Clear Cell Sarcoma
Phase 2
Waitlist Available
Research Sponsored by NantPharma, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing AMG 337, a medication, in patients with advanced or metastatic clear cell sarcoma that has a specific genetic change. The goal is to see if the medication can stop the cancer cells from growing by blocking their internal communication systems. AMG 337 is taken orally and targets specific cancer cells.
Eligible Conditions
- Clear Cell Sarcoma of Soft Tissue
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Objective Response Rate (ORR)
Secondary study objectives
Incidence of Treatment-Emergent Adverse Events (Safety And Tolerability)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: AMG 337Experimental Treatment1 Intervention
AMG 337 will be administered in patients with advanced or metastatic clear cell sarcoma
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
AMG 337
2014
Completed Phase 2
~130
Find a Location
Who is running the clinical trial?
NantPharma, LLCLead Sponsor
2 Previous Clinical Trials